cellcept
roche registration gmbh - mikofenolato mofetilis - dantų atmetimas - imunosupresantai - cellcept skirtas vartoti kartu su ciklosporinu ir kortikosteroidais transplantato ūminio atmetimo profilaktikai pacientams, vartojantiems alogeninės inkstų, širdies ar kepenų transplantacijos.
norestal
norameda, uab - escitalopramas - plėvele dengtos tabletės - 10 mg; 20 mg - escitalopram
seedron®
adama - takus koncentratas - fludioksonilas + tebukonazolas - beicai
gigant®
adama - koncentruota suspensija - izopirazamas + protiokonazolas - fungicidai
mavrik®
adama - aliejinė vandens emulsija - tau–fluvalinatas - insekticidai
timeline® fx
adama - koncentruota emulsija - florasulamas + fluroksipiras + pinoksadenas - herbicidai
avaglim
smithkline beecham ltd - rosiglitazone, glimepiride - cukrinis diabetas, 2 tipas - narkotikai, vartojami diabetu - avaglim yra nurodyta, gydant 2 tipo cukriniu diabetu sergantiems pacientams, kurie negali pasiekti pakankamai glycaemic kontrolę, optimalią dozę sulfonilkarbamido dariniai monotherapy, ir kam metforminas yra netinkamas, nes kontraindikacija ar netolerancija.
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroksabanas - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitromboziniai vaistai - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
flixonase
glaxosmithkline dungarvan limited - flutikazono propionatas - nosies purškalas (suspensija) - 50 µg/išpurškime - fluticasone
fluticasone propionate gsk
glaxosmithkline trading services limited - flutikazono propionatas - nosies purškalas (suspensija) - 50 µg/išpurškime - fluticasone